Watchlist Price Alert

Atossa Therapeutics Inc. (ATOS)

NASDAQ: ATOS · Real-Time Price · USD

0.90

0.04 (4.68%)

At close: Jun 06, 2025, 3:59 PM

0.91

0.74%

After-hours: Jun 06, 2025, 05:57 PM EDT

4.68% (1D)

Bid	0.9
Market Cap	116.67M
Revenue (ttm)	n/a
Net Income (ttm)	-26.34M
EPS (ttm)	-0.2
PE Ratio (ttm)	-4.52
Forward PE	-3.18
Analyst	Buy

Ask	0.92
Volume	596,342
Avg. Volume (20D)	679,898
Open	0.87
Previous Close	0.86
Day's Range	0.85 - 0.91
52-Week Range	0.55 - 1.66
Beta	0.90

About ATOS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ATOS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ATOS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

News

2 weeks ago · accessnewswire.com

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines f...

3 weeks ago · zacks.com

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

2 months ago · zacks.com

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy

Atossa Genetics (ATOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · seekingalpha.com

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Atossa Therapeutics, Inc. (NASDAQ:ATOS ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Michael Parks - VP of Investor and Public Relations Steven Quay - President and...